Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Cocrystal Pharma, Inc./ 8-K

Current Report · Items 7.01, 9.01 · 8-K

Cocrystal Pharma, Inc.

COCPNASDAQEQUITYCurrent

Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On June 3, 2026, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing James Sapirstein’s appointment as Chief Executive Officer. A copy of the press release is furnished as Exhibit 99.1.…

Filed Jun 3, 2026Accepted Jun 3, 2026, 7:00 AM EDTCIK 1412486Accession 0001493152-26-026965
View company →Permanent SEC source ↗
Share

Company context

Cocrystal is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising discovery, preclinical and clinical stage antiviral compounds for unmet medical needs caused by coronavirus, influenza virus and norovirus.

Current securities

COCPNASDAQ · EQUITY · Current

Recent company filings

  1. Regulation FD DisclosureSep 9, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 18, 2026
  3. Regulation FD DisclosureAug 17, 2026
  4. 10-Q filingAug 13, 2026
  5. 4 filingAug 6, 2026

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On June 3, 2026, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing James Sapirstein’s appointment as Chief Executive Officer. A copy of the press release is furnished as Exhibit 99.1. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer BOTHELL, Wash., June 3, 2026 - Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin will continue as Chief Financial Officer. “James brings the right experience in the biopharma business as we’re accelerating the advancement of multiple clinical programs,” said Roger Kornberg, Ph. D., Chairman of Cocrystal Pharma. “We have known him for many years, and our management team and board are appreciative of his decision to …

Open exhibit ↗